NIH R01 · 2025
Neuroprotective Strategy: Novel Purine Derivatives for Neonatal Hypoxia-ischemia
PROJECT SUMMARY/ABSTRACT Hypoxia-ischemia (HI) is the one of leading causes of neurodevelopmental morbidities in preterm and full-term infants. The only therapeutic strategy to treat HI encephalopathy (HIE) in full term infants is hypothermia, which is only partially protective. The only therapy for HI in preterm infants is supportive care. HI brain injury is characterized by a pronounced inflammatory response along with early structural alterations in the blood-brain barrier (BBB)/neurovasculature unit (NVU). Both inflammation and BBB abnormalities predispose to neuronal damage. In the current proposal, we investigate a novel family of molecules, which are purine derivatives (PDD), acting…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.